BCX9930

Phase 2Small molecule

BBioCryst Pharmaceuticals

BCX9930 is one of 31 small molecule programs targeting Complement 3 Glomerulopathy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Complement 3 GlomerulopathyActive, not recruiting

Paroxysmal Nocturnal HemoglobinuriaActive, not recruiting

Complement 3 GlomerulopathyPhase 2

Active, not recruiting

Paroxysmal Nocturnal HemoglobinuriaPhase 2

Active, not recruiting

Competition

Competitive Landscape

39 competitors in Paroxysmal Nocturnal Hemoglobinuria

#DrugCompanyPhaseTrials

VEOPOZ

Regeneron

Phase 3

7 2

Fabhalta

Novartis

Phase 3

2 3

Cemdisiran

Regeneron

Phase 3

7 4

Empaveli

Apellis Pharmaceuticals

Phase 3

2 5

Neupogen

EEastern Cooperative Oncology Group

Phase 2

1 6

Cytoxan

BBaxter Healthcare Corporation

Phase 2

1 7

PIASKY

Roche

Phase 2

4 8

LNP023

Novartis

Phase 2

2 9

Glucocorticoids

Novartis

Phase 2

2 10

LFG316

Novartis

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Paroxysmal Nocturnal Hemoglobinuria4 trials

BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants Not Receiving Other Complement Inhibitor Therapy

Terminated·BBioCryst Pharmaceuticals·Phase 2·NCT05116787·12 enrolled

BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor Therapy

Terminated·BBioCryst Pharmaceuticals·Phase 2·NCT05116774·12 enrolled

Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria

Terminated·BBioCryst Pharmaceuticals·Phase 2·NCT05741346·28 enrolled

Show 1 more trial

A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Terminated·BBioCryst Pharmaceuticals·Phase 2·NCT04702568·19 enrolled

PNH1 trial

First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNH

Completed·BBioCryst Pharmaceuticals·Phase 1/2·NCT04330534·168 enrolled

Complement 3 Glomerulopathy1 trial

Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)

Terminated·BBioCryst Pharmaceuticals·Phase 2·NCT05162066·2 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for BCX9930. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BCX9930 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BCX9930. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BioCryst Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBioCryst Pharmaceuticals

BCX9930

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Paroxysmal Nocturnal Hemoglobinuria4 trials

PNH1 trial

Complement 3 Glomerulopathy1 trial

References

Drug Info

Quick Facts

Related News